Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Cephalon, Inc. Clear all

Conditions: Asthma
Interventions: Reslizumab, Saline; Biological · Other
Lead sponsor: Ception Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more

Conditions: Systemic Lupus Erythematosus
Interventions: CEP-33457; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more

Conditions: Chronic Low Back Pain
Interventions: ORAVESCENT Fentanyl Citrate; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 17
States / cities: Jonesboro, Arkansas • Bakersfield, California • San Diego, California + 13 more

Conditions: Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions: Armodafinil 100 to 250 mg/day; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more

Conditions: ADHD
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 39
States / cities: Scottsdale, Arizona • Irvine, California • Northridge, California + 35 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Bendamustine HCl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Generalized Anxiety Disorder
Interventions: Gabitril; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 19
States / cities: Los Angeles, California • Newport Beach, California • San Diego, California + 14 more

Conditions: Narcolepsy, Obstructive Sleep Apnea, Shift Work Sleep Disorder
Interventions: Modafinil/armodafinil; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: Female only
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2023
U.S. locations: 1
States / cities: West Chester, Pennsylvania

Conditions: Non-Hodgkin's Lymphoma
Interventions: bendamustine and rituximab; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 25
States / cities: Anchorage, Alaska • Concord, California • La Verne, California + 22 more

Conditions: Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 38
States / cities: Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more

Conditions: Non-Hodgkin's Lymphoma (NHL)
Interventions: Bendamustine hydrochloride, Ofatumumab; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 34
States / cities: Birmingham, Alabama • Beverly Hills, California • Stamford, Connecticut + 30 more

Conditions: Pain, Cancer, Sickle Cell Anemia, Severe Burns
Interventions: ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]); Drug
Lead sponsor: Cephalon; Industry
Eligibility: 3 Years to 15 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 26
States / cities: Little Rock, Arkansas • Orange, California • Palo Alto, California + 21 more

Conditions: Narcolepsy
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more

Conditions: Traumatic Brain Injury
Interventions: Armodafinil; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 61
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more

Conditions: Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more

Conditions: Anxiety Disorders
Interventions: Gabitril; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 86
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 73 more

Conditions: Multiple Myeloma
Interventions: SDX-101 (R-Etodolac); Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 8
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more

Conditions: Depression
Interventions: Armodafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 50 more

Conditions: Attention Deficit/Hyperactivity Disorder, ADHD
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 57
States / cities: Birmingham, Alabama • Mesa, Arizona • Fort Smith, Arkansas + 53 more

Conditions: Pain
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more

Conditions: Sleep Apnea, Obstructive
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 60
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more

Conditions: Myelodysplastic Syndrome
Interventions: Decitabine, Arsenic Trioxide and Ascorbic Acid; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: CEP-33457, Placebo; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more

Conditions: Multiple Myeloma
Interventions: Bendamustine, Bortezomib, Dexamethasone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 13
States / cities: Thousand Oaks, California • Fort Myers, Florida • Baton Rouge, Louisiana + 9 more

Search by objective public record fields.

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

The Nuvigil and Provigil Pregnancy Registry

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.

Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy